The estimated Net Worth of Venture Management Co Iii L... is at least $8.88 Million dollars as of 22 February 2005. Venture L owns over 250,000 units of Momenta Pharmaceuticals stock worth over $3,826,999 and over the last 20 years Venture sold MNTA stock worth over $5,051,553.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Venture L MNTA stock SEC Form 4 insiders trading
Venture has made over 12 trades of the Momenta Pharmaceuticals stock since 2004, according to the Form 4 filled with the SEC. Most recently Venture sold 250,000 units of MNTA stock worth $1,755,000 on 22 February 2005.
The largest trade Venture's ever made was selling 250,000 units of Momenta Pharmaceuticals stock on 22 February 2005 worth over $1,755,000. On average, Venture trades about 52,769 units every 5 days since 2004. As of 22 February 2005 Venture still owns at least 72,923 units of Momenta Pharmaceuticals stock.
You can see the complete history of Venture L stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Momenta Pharmaceuticals
Over the last 20 years, insiders at Momenta Pharmaceuticals have traded over $110,027,424 worth of Momenta Pharmaceuticals stock and bought 827,300 units worth $5,505,611 . The most active insiders traders include Christoph H Westphal, Craig A Wheeler, and Peter Barrett. On average, Momenta Pharmaceuticals executives and independent directors trade stock every 6 days with the average trade being worth of $448,442. The most recent stock trade was executed by Ian Fier on 20 August 2020, trading 1,808 units of MNTA stock currently worth $94,323.
What does Momenta Pharmaceuticals do?
Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA.
What does Momenta Pharmaceuticals's logo look like?
Complete history of Venture L stock trades at Alnylam Pharmaceuticals Inc and Momenta Pharmaceuticals
Momenta Pharmaceuticals executives and stock owners
Momenta Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Donna Roy Grogan,
Director -
Jose Carlos Gutierrez Ramos,
Director -
Santiago Arroyo,
SVP, Chief Medical Officer -
Craig A Wheeler,
President & CEO -
Corey N. Fishman,
Director -
Marsha Fanucci,
Director -
James R Sulat,
Director -
Bruce Leicher,
SVP & General Counsel -
Matthew P. Ottmer,
Chief Operating Officer -
Richard P Shea,
VP, Chief Financial Officer -
Georges Gemayel,
Director -
Thomas P Koestler,
Director -
Steven C Gilman,
Director -
Bruce Downey,
Director -
Elizabeth Stoner,
Director -
Scott M Storer,
SVP, CFO -
James M. Roach,
Senior VP, Development and Chi -
Michelle Robertson,
Chief Financial Officer -
Anthony M. Manning,
Chief Scientific Officer -
Jo Ann Beltramello,
Chief HR and Inf. Officer -
Alejandra Carvajal,
Chief Legal Officer -
Ian Fier,
Chief Mfg and Program Officer -
Young Kwon,
Chief Financial & Bus. Officer -
Peter Barrett,
Director -
Peter Barton Hutt,
Director -
Paul D Goldenheim,
Director -
Stephen B Brugger,
VP, Strategic Prod Devl. -
John L Zabriskie,
Director -
Ram Sasisekharan,
Director -
Venture Management Co Iii L...,
-
Christoph H Westphal,
Director -
Venture Fund V Lpatlas Vent...,
-
Bennett M Shapiro,
Director -
Stephen T Reeders,
Director -
International Life Sciences...,
10% owner -
Ganesh Venkataraman,
VP, Technology -
Venture Fund V Lpatlas Vent...,
-
Venture Management Co Iii L...,
-
Michael Franken,
President, Biosimilars Busines -
Robert Langer,
Director -
Carron Shmerling Lisa,
V.P., Legal Affairs -
John E Bishop,
VP Pharma Sciences & Manufact -
Susan K Whoriskey,
VP, Licensing and Bus. Develop -
Alan L Crane,
President and CEO -
Venture Fund V Lpatlas Vent...,
-
John K Clarke,
Director -
Jane F Barlow,
Director -
Agnieszka Cieplinska,
Chief Accounting Officer (PAO)